<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02907320</url>
  </required_header>
  <id_info>
    <org_study_id>DC0982 GE 2 04</org_study_id>
    <nct_id>NCT02907320</nct_id>
  </id_info>
  <brief_title>EXPLORATORY ASSESSMENT OF THE EFFECTS OF CYCLO 3 ® FORT (Ruscus Extract, Hesperidin Methyl Chalcone, Ascorbic Acid) OR MICRONISED PURIFIED FLAVONOID FRACTION ON VASCULAR PARAMETERS AND BIOMARKERS IN WOMEN SUFFERING FROM CHRONIC VENOUS DISEASE (CEAP C2 OR C3), OVER 8 WEEKS</brief_title>
  <official_title>EXPLORATORY ASSESSMENT OF THE EFFECTS OF CYCLO 3 ® FORT (Ruscus Extract, Hesperidin Methyl Chalcone, Ascorbic Acid) OR MICRONISED PURIFIED FLAVONOID FRACTION ON VASCULAR PARAMETERS AND BIOMARKERS IN WOMEN SUFFERING FROM CHRONIC VENOUS DISEASE (CEAP C2 OR C3), OVER 8 WEEKS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eurotrials Brasil Consultores Cientificos Ltda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Venous Disorder is the most prevalent vascular disease. It is multifactorial
      pathology that has an important impact on quality of life and represents a significant public
      health concern, due to its very high frequency in all European and American (north and south)
      countries.

      Venous pathology develops when venous pressure is increased and return of blood is impaired
      through several mechanisms. Wish induce leg symptoms (tingling, aching, burning, pain, muscle
      cramps, sensation of swelling, sensations of throbbing or heaviness, itching skin, restless
      legs, leg tiredness and/or fatigue.

      The aims of this research is to study the effects on microcirculatory activity (activity on
      very small vessels) of CYCLO 3 ® FORT, MPFF (Micronised Purified Flavonoid Fraction) and
      Placebo after 8 week of treatment by Microscan, and Duplex, two imaging non-invasive
      technologies will be performed to obtain measurements of microcirculatory parameters in
      standardized and reproducible conditions for all the participants. In addition, will assess,
      in blood samples, the inflammatory biomarkers .
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date type="Anticipated">December 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Capillary diameter</measure>
    <time_frame>From baseline (Day 0) to Day 56</time_frame>
    <description>Measure by microscan of capillary diameter, in micrometer on the worst leg (CEAP classification C2 or C3) at Baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of venoconstriction activity</measure>
    <time_frame>From baseline (Day 0) to Day 56</time_frame>
    <description>Measure by Duplex-scan of vein diameter in millimeter on the worst leg (CEAP classification C2 or C3) at Baseline.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Venous Disease Classification (CEAP): C2 or C3</condition>
  <arm_group>
    <arm_group_label>CYCLO 3 ® FORT and placebo MPFF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MPFF = Micronized Purified Flavonoid Fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MPFF and placebo CYCLO 3 ® FORT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MPFF = Micronized Purified Flavonoid Fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>MPFF = Micronized Purified Flavonoid Fraction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYCLO 3 ® FORT</intervention_name>
    <arm_group_label>CYCLO 3 ® FORT and placebo MPFF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MPFF</intervention_name>
    <arm_group_label>MPFF and placebo CYCLO 3 ® FORT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo CYCLO 3 ® FORT</intervention_name>
    <arm_group_label>MPFF and placebo CYCLO 3 ® FORT</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo MPFF</intervention_name>
    <arm_group_label>CYCLO 3 ® FORT and placebo MPFF</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Inclusion criteria

               -  Non-menopausal women aged from 18 to 50 years

               -  Symptomatic Primary chronic disorder C2 or C3 of advanced CEAP

               -  Regular menstrual cycle

               -  Use an efficient method of contraception

               -  Having signed her written informed

          2. Non-inclusion criteria 2.1 Related to pathology:

               -  Superficial and or deep venous thrombosis

               -  Venous insufficiency including history of deep venous thrombosis, post thrombotic
                  syndrome, venous dysplasia, compressive syndrome

               -  History of venous strapping or phlebotomy/ surgery of the evaluated leg

               -  Sclerosing injection within 6 month before inclusion

               -  Oedema from other etiology

               -  Paresthesia, cramps of the lower limbs from other origin 2.2 Related to
                  treatment:

               -  Hypersensitivity, allergy or intolerance to study drugs

               -  Iron storage disorder

               -  Intake of venotonic treatment (oral or topic) ,triptan ,diuretics ,calcium
                  blockers, beta blockers, ACE inhibitors, angiotensine II inhibitors,
                  vasodilatators and/or vasoconstrictors within 1 month before inclusion

               -  Intake of NSAID,corticosteroids,ergotamine, dihydroergotamine or any ergot
                  alkaloids,vitamin C nutraceutical or phytotherapy products with potential
                  venotonic effect within 2 weeks before inclusion 2.3 Related to the population:

               -  History of diabetes

               -  BMI≥ 30

               -  Grade V and VI on Fitzpatrick classification
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zahida Issiakhem Belkaid, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pierre Fabre Medicament</affiliation>
  </overall_official>
  <removed_countries>
    <country>Brazil</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2016</study_first_submitted>
  <study_first_submitted_qc>September 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>February 17, 2017</last_update_submitted>
  <last_update_submitted_qc>February 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

